Navigation Links
City of Hope Uses Isilon IQ to Advance Fight Against Life-Threatening Diseases
Date:4/28/2009

World-Renowned Biomedical Research and Treatment Facility Deploys Isilon Scale-out NAS to Power DNA Sequencing Workflow, Accelerating Cancer, Diabetes, and HIV/AIDS Research

SEATTLE, April 28 /PRNewswire-FirstCall/ -- Isilon(R) Systems (Nasdaq: ISLN), the proven leader in scale-out NAS, today announced that City of Hope, a National Cancer Institute-designated Comprehensive Cancer Center, has deployed Isilon IQ to accelerate its next-generation DNA sequencing operations and speed time-to-results for groundbreaking research for cancer, diabetes, and HIV/AIDS. Using Isilon scale-out NAS, City of Hope has unified massive amounts of mission-critical genomic data, streamlining access and analysis to increase workflow productivity while reducing storage management costs.

"Genomic research may very well transform modern medicine by uncovering the genetic precursors for a multitude of life-threatening diseases," said Dr. Richard Jove, director of Beckman Research Institute, City of Hope. "Yet these connections can only be made with the right data, at the right time. With Isilon IQ, we now have the storage infrastructure in place to not only accelerate our DNA sequencing workflow, but also seamlessly expand our capacity to support critical research in the areas of proteomics, chemiformatics and imaging."

City of Hope is one of only 40 National Cancer Institute-designated Comprehensive Cancer Centers in the United States and a founding member of the National Comprehensive Cancer Network. An independent biomedical research, treatment and education institution, its leading-edge research aims to advance the fight against cancer, diabetes, HIV/AIDS and other life-threatening diseases. By combining next-generation technology with the latest genomic, proteomic, chemiformatic and imaging research methodologies, City of Hope discoveries have led to the development of some of today's most notable medical breakthroughs, including the first synthetic human insulin and human growth hormone, as well as the widely used cancer fighting drugs Herceptin, Rituxan and Avastin.

Working with leading Isilon value-added systems integrator Talon Data Systems, City of Hope has deployed Isilon IQ to centralize enormous amounts of mission-critical genomic sequencing data into a single, high-performance, highly scalable shared pool of storage, enabling researchers to directly store and analyze DNA sequencing data without interruption or downtime. Isilon scale-out NAS, featuring its OneFS(R) operating system software, provides City of Hope with an efficient, easy-to-manage storage infrastructure that accelerates productivity while reducing storage management overhead, enabling City of Hope researchers to spend their time on science, not on storage.

"City of Hope has been leading the fight against life-threatening disease for nearly 100 years, enabling some of modern medicine's most significant advances," said Ram Appalaraju, vice president of marketing, Isilon Systems. "By using Isilon IQ to power their groundbreaking research, City of Hope is demonstrating the enormous value our scale-out NAS solutions can deliver for today's leading bioinformatics organizations."

Talon Data Systems is a leading supplier of enterprise-class storage, networking, and Wide Area Network (WAN) solutions. By providing City of Hope with initial workflow analysis and system installation, as well as ongoing support, Talon Data ensured the seamless integration of the Isilon solution with City of Hope's IT infrastructure, accelerating system deployment to maximize results.

"City of Hope's next-generation research necessitates a truly mission-critical storage infrastructure, making non-disruptive system installation and efficient, ongoing operation vital," said Tom Shearer, principal, Talon Data Systems. "By combining Isilon's industry-leading ease-of-use with our expertise in workflow design, service and support, we were able to provide City of Hope with the best storage solution to meet their needs while maintaining the full integrity of their IT environment."

About Isilon Systems

Isilon Systems (NASDAQ: ISLN) is the proven leader in scale-out NAS. Isilon's clustered storage and data management solutions drive unique business value for customers by maximizing the performance of their mission-critical applications, workflows, and processes. Isilon enables enterprises and research organizations worldwide to manage large and rapidly growing amounts of file-based data in a highly scalable, easy-to-manage, and cost-effective way. Information about Isilon can be found at http://www.isilon.com.

The names of companies mentioned herein are the trademarks of their respective owners.


'/>"/>
SOURCE Isilon Systems
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Personal Genome Project Deploys Isilon IQ Storage to Transform Genomic Research
2. Isilon Named Best of Show at Bio-IT World 2008
3. HBO, Warner Bros. Employee Initiatives and the Alzheimers Association, California Southland Chapter Present a Free, Public, Advance Screening of THE ALZHEIMERS PROJECT: Caregivers
4. Future for radioembolisation in patients with advanced hepatocellular carcinoma
5. Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers
6. Educating referring clinicians about advanced imaging leads to drop in imaging exams
7. Wound Management Technologies, Inc. Announces the Presentation of Evidence Based Clinical Studies at the Symposium on Advanced Wound Care Conference in Dallas
8. New advances in cancer research to be highlighted at University of Leicester
9. Singapore Adopts Advanced Genetic Engineering in Orthopedic Surgery
10. Millstone Medical Outsourcing Celebrates New Fall River Facility, Designed to Meet Demand for Advanced Inspection, Clean Room Services
11. Circadiance Launches the New SleepWeaver(TM) ADVANCE All Cloth CPAP Mask
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... While new U.S. opioid ... physicians are not legally required to follow them. In the absence of federal ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, strongly ...
(Date:5/23/2016)... ... ... the upcoming airing of Innovations with Ed Begley, Jr., ... 4:00pET via Fox Business. , The show will explore ... safely and rapidly develop cures for mosquito-borne, emerging infectious ...
(Date:5/23/2016)... , ... May 23, 2016 ... ... Size for Verification and Validation:, Tools to Safely Speed Your Device to ... http://www.fdanews.com/bestdevicesamplesizevv                  , Today's FDA inspectors focus like lasers on device ...
(Date:5/23/2016)... (PRWEB) , ... May 23, 2016 , ... ... the action analytics leader as Chief Medical Officer. Dr. O’Connor’s deep expertise in ... product development and client services teams who deliver best-in-class solutions and transformative technologies ...
(Date:5/23/2016)... Valley, California (PRWEB) , ... May 23, 2016 ... ... clinical communications and solutions for healthcare providers announced today that AGNITY MobileCare™ Platform ... and health collaboration applications as a part of its M-Health Solution. Tech Mahindra ...
Breaking Medicine News(10 mins):
(Date:5/19/2016)... Israel , May 19, 2016 ... the "Company"), an emerging global ophthalmic company focused on ... candidates which address ophthalmic conditions, announced today that it ... Italy ) for the manufacturing, distribution, marketing ... for the treatment of dry eye syndrome (DES) and ...
(Date:5/19/2016)... May 19, 2016 A ... World Biopsy Devices Market Opportunities and Forecasts, 2014 ... market generated $1,621 million in 2015. The MRI-guided ... and is expected to maintain this trend over ... http://photos.prnewswire.com/prnh/20140911/647229 ) , To know ...
(Date:5/19/2016)... BioLineRx Ltd. (NASDAQ/TASE: BLRX) announced ... of multiple cancer and hematological indications, will be presented ... titled " Clinical response in relapsed/refractory AML patients correlates ... a potent CXCR4 antagonist; results of a Phase 2a ... the European Hematology Association 21st Congress, to be held ...
Breaking Medicine Technology: